Health Care Reform and Possible Effects on Innovative Therapies: Cancer as a Case Study : Hearing Before the Subcommittee on Technology, Environment, and Aviation of the Committee on Science, Space, and Technology, U.S. House of Representatives, One Hundred Third Congress, Second Session, February 2, 1994, Volume 4U.S. Government Printing Office, 1994 - 198 pages |
From inside the book
Results 1-5 of 33
Page 3
... issue that we need to explore , so I am very interested in hearing your testimony . Furthermore , biotechnology is a very important issue not only in New Jersey , but if you keep heading up in the Northeast , there is a tremendous ...
... issue that we need to explore , so I am very interested in hearing your testimony . Furthermore , biotechnology is a very important issue not only in New Jersey , but if you keep heading up in the Northeast , there is a tremendous ...
Page 5
... issue for all Americans . The impact of health care reform will have far eaching consequences in lives of all Americans . The impact of health care reform n the biomedical technology industry ia a cross cutting issue which touches on ...
... issue for all Americans . The impact of health care reform will have far eaching consequences in lives of all Americans . The impact of health care reform n the biomedical technology industry ia a cross cutting issue which touches on ...
Page 22
... issue , not just a policy issue . Let me turn to a third chart which compares international price for the leading biotec drugs in the U.S. and Japan . It shows that the prices of these drugs tends to be much highe in Japan ( which sets ...
... issue , not just a policy issue . Let me turn to a third chart which compares international price for the leading biotec drugs in the U.S. and Japan . It shows that the prices of these drugs tends to be much highe in Japan ( which sets ...
Page 23
... point is that the health care market works when breakthrough drugs are developed . The market doesn't work when breakthrough drugs aren't developed . How we price breakthrough drugs once they are developed is an issue 14 23.
... point is that the health care market works when breakthrough drugs are developed . The market doesn't work when breakthrough drugs aren't developed . How we price breakthrough drugs once they are developed is an issue 14 23.
Page 24
... issue only if the drugs are , in fact , developed . Companies that do develop breakthrough drugs feel market pressures as soon as they market the drug . The real period of exclusivity in the market is likely to be 2-4 years , not the 17 ...
... issue only if the drugs are , in fact , developed . Companies that do develop breakthrough drugs feel market pressures as soon as they market the drug . The real period of exclusivity in the market is likely to be 2-4 years , not the 17 ...
Other editions - View all
Common terms and phrases
administration Administration's American antibody biotech biotech companies biotech firms biotechnology companies biotechnology industry Biotechnology Industry Organization bone marrow transplant breakthrough drugs breast cancer CANCE cancer cells cancer patients cancer research capital Chairman chemotherapy clinical trials Clinton colon cancer colorectal cancer committee competition Congress Curd cure disease doctors drug companies drug costs drug prices Duke effective Federal FELDBAUM funding gastrointestinal gene therapy Genentech global going health care costs health care reform health care system HOKE hospital human impact incidence increased innovation investment investors Japan Johnson KLEIN manufacturing medicine million National Cancer Institute percent pharmaceutical industry prescription President price controls Price Regulation profits proposed protein receptor regulatory research and development result spending subcommittee surgery Thank therapeutic Tim Valentine treat TREATMENT OF COLORECTAL tumor United VALENTINE WAGNER-JOHNSON women
Popular passages
Page 75 - Never doubt that a small group of thoughtful committed citizens can change the world. Indeed it's the only thing that ever has.
Page 140 - The purpose of the Agency is to enhance the quality, appropriateness, and effectiveness of health care services, and access to such services, through the establishment of a broad base of scientific research and through the promotion of improvements in clinical practice (including the prevention of diseases and other health conditions) and in the organization, financing, and delivery of health care services.
Page 179 - R&D as a percent of sales for seven major drug companies is compared to Federal health care research spending as a percent of health care costs. This graph shows that major drug companies have doubled their...
Page 128 - Kaposi's sarcoma (KS) was examined with the use of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.
Page 52 - Reforms Needed in the Organization, Management, and Resources of the Food and Drug Administration's Center for Devices and Radiological Health.
Page 179 - One of out of every three living Americans will die of cancer. Currently, there are over 8 million cancer patients in the US You can think of them as having tested positive for cancer. I talk with hundreds of cancer patients every year. I get phone calls every day and I know their problems with the health care system. First, and foremost, they haven't got a cure for their disease.
Page 182 - Lower market value* mean that the cost of capital is going up and less capital is available. ultimately, capital flows are reflected in research budgets as well as in prices . As I mentioned, I have been involved in several high tech ventures. Currently* "word on the street...
Page 4 - I thank all of you for being here, and I look forward to hearing your testimony. Thank you, Mr. Chairman.
Page 67 - I would be pleased to answer any questions you might have. Thank you. [The prepared statement of Mr.
Page 2 - Thank you very much, Mr. Chairman. I first want to express my...